News & Updates
Filter by Specialty:
Ixa-dex, pom-dex both effective in heavily pretreated relapsed, refractory multiple myeloma
Ixazomib-dexamethasone (ixa-dex) and pomalidomide-dexamethasone (pom-dex) achieve comparable levels of efficacy and safety in relapsed and refractory multiple myeloma (RRMM) patients who had already been exposed to prior lenalidomide-based regimens, a recent study has found.
Ixa-dex, pom-dex both effective in heavily pretreated relapsed, refractory multiple myeloma
08 Jun 2022
Antihypertensive drug does not lower death risk in HFrEF patients
Use of an antihypertensive drug does not appear to reduce the risk of all-cause mortality or hospital readmission in hospitalized older patients with heart failure with reduced ejection fraction (HFrEF) who are receiving contemporary treatments for HF, reveals a recent study.
Antihypertensive drug does not lower death risk in HFrEF patients
08 Jun 2022
Long-term steroid OK for RA but challenges guidelines
Contrary to what current guidelines advocate, long-term use of corticosteroid works fine in older patients with rheumatoid arthritis (RA), suggests the much-anticipated GLORIA* trial presented at EULAR 2022.
Long-term steroid OK for RA but challenges guidelines
08 Jun 2022
Microbiome-based therapy for recurrent CDI hits mark in patients with comorbidities
The investigational microbiota-based live biotherapeutic RBX2660 is safe and averts repeat episodes of Clostridioides difficile infection (CDI) across patient populations with comorbid conditions, as shown in a study presented at Digestive Disease Week (DDW) 2022.
Microbiome-based therapy for recurrent CDI hits mark in patients with comorbidities
07 Jun 2022
High-dose iberdomide shows promise in phase II SLE trial
In a phase II trial evaluating three doses of the high-affinity cereblon modulator iberdomide, the 0.45-mg dose demonstrated superiority over placebo for individuals with active, moderate-to-severe systemic lupus erythematosus (SLE).